Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva versus Alimta or Taxotere in previously platinum-treated advanced non-small cell lung cancer
2005-003220-19Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Tarceva, Alimta and Taxotere (3 arms). Primary endpoint: Overall survival. Started Oct 2005; status: completed.
02
Drugs
erlotinibpemetrexeddocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-003220-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003220-19.